OXIGENE'S CA4P RECEIVES OK IN UK

A A

Oxigene has received regulatory clearance in the UK to begin its first Phase III clinical trial with its lead product candidate, Combretastatin A4P (CA4P).

The study will be a randomized, double blind, placebo-controlled trial. The trial is expected to enroll approximately 370 patients who have not had prior treatment for non-small cell lung cancer and who will be randomized into either a control group or a treatment group. The primary objective of this trial is to compare median survival time of patients in the treatment group versus the control group.